Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- None.
- None.
A live webcast of the fireside chat is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the event will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404214878/en/
Investor Relations:
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media:
David Rosen
Argot Partners
cartesian@argotpartners.com
Source: Cartesian Therapeutics, Inc.
FAQ
When will Cartesian Therapeutics, Inc. (RNAC) participate in the fireside chat at the 23rd Annual Needham Virtual Healthcare Conference?
What is the focus of Cartesian Therapeutics, Inc. (RNAC) in the fireside chat at the conference?
Where can the live webcast of the fireside chat be accessed?
Will there be an archived replay of the fireside chat available?
